Medtronic PLC $MDT Shares Acquired by Czech National Bank

Czech National Bank increased its holdings in shares of Medtronic PLC (NYSE:MDT) by 3.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 338,206 shares of the medical technology company’s stock after acquiring an additional 12,791 shares during the period. Czech National Bank’s holdings in Medtronic were worth $32,488,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Delos Wealth Advisors LLC purchased a new position in Medtronic during the second quarter worth approximately $27,000. Corundum Trust Company INC acquired a new stake in Medtronic in the third quarter valued at approximately $27,000. Valley Wealth Managers Inc. purchased a new stake in shares of Medtronic in the third quarter valued at approximately $29,000. Board of the Pension Protection Fund acquired a new position in shares of Medtronic during the 4th quarter worth approximately $29,000. Finally, GoalVest Advisory LLC acquired a new position in shares of Medtronic during the 4th quarter worth approximately $29,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This trade represents a 61.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.26% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on MDT. Wall Street Zen cut shares of Medtronic from a “buy” rating to a “hold” rating in a research note on Sunday, March 1st. Citigroup assumed coverage on shares of Medtronic in a research report on Tuesday, February 3rd. They set a “buy” rating and a $117.00 price objective for the company. Truist Financial decreased their price objective on shares of Medtronic from $107.00 to $103.00 and set a “hold” rating on the stock in a report on Wednesday, February 18th. Sanford C. Bernstein boosted their target price on shares of Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a research note on Friday, January 9th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $110.74.

Medtronic Stock Up 1.5%

NYSE MDT opened at $87.84 on Thursday. The business has a fifty day moving average price of $96.22 and a 200 day moving average price of $96.58. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The company has a market cap of $112.77 billion, a P/E ratio of 24.47, a P/E/G ratio of 2.22 and a beta of 0.71. Medtronic PLC has a one year low of $79.55 and a one year high of $106.33.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be paid a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend is Friday, March 27th. Medtronic’s dividend payout ratio is currently 79.11%.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Distribution deal expands Medtronic’s chronic‑pain portfolio — Medtronic agreed to distribute Merit Medical’s FDA‑cleared ViaVerte basivertebral nerve ablation (BVNA) system, adding a minimally invasive, implant‑free option for chronic vertebrogenic low‑back pain and broadening its interventional pain offering. This can support revenue growth in a high‑demand pain segment. Medtronic and Merit Medical Systems enter into agreement
• Positive Sentiment: FDA expands indication for OmniaSecure lead — The FDA cleared an expanded indication that allows placement of Medtronic’s OmniaSecure defibrillation lead in the left bundle branch area for conduction‑system pacing, strengthening its electrophysiology product lineup and supporting growth in cardiac rhythm management. Medtronic Announces FDA Approval for Expanded Indication of OmniaSecure
• Positive Sentiment: Spin‑off of diabetes unit remains a strategic catalyst — Coverage and commentary note Medtronic’s planned diabetes‑unit spin‑off later this year; separating the high‑growth diabetes business may unlock valuation for both the diabetes standalone and the remaining higher‑margin device franchises. This is a medium‑term positive for investor sentiment. Medtronic to Spin-Off High-Growth Diabetes Unit
• Neutral Sentiment: Analyst sentiment and “undervalued” mentions — Recent writeups and analyst coverage label MDT a moderate buy/undervalued blue‑chip, which can support steadier investor interest but is unlikely to trigger large moves absent fundamentals. Medtronic Given Consensus Rating of “Moderate Buy”
• Negative Sentiment: Guidance cut and charge tied to MiniMed approvals — Medtronic lowered its 2026 earnings outlook, citing a private‑equity related charge connected to MiniMed approval updates. That revision is a direct near‑term earnings headwind and a clear negative on short‑term sentiment. Medtronic cuts 2026 guidance on private equity charge related to MiniMed approval

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).